Publications by authors named "Dorothy Kai-Lai Chow"
Article Synopsis
- Recent research using 16S rRNA profiling has uncovered a complex microbiota in the stomach mucosa, revealing 133 phylotypes from eight bacterial phyla, indicating a diverse microbial environment.
- Helicobacter pylori and NSAID use are known contributors to gastritis, but the influence of other stomach microbiota members on gastric diseases is still not well understood.
- The study found significantly higher levels of the Firmicutes phylum and Streptococcus genus in patients with antral gastritis compared to healthy individuals, suggesting that these specific genera may be key indicators of microbiota changes linked to gastric diseases.
Article Synopsis
- This study investigates the long-term outcomes of patients with bleeding peptic ulcers that are neither associated with Helicobacter pylori nor NSAID use.
- Over a 7-year period, the research shows that patients with idiopathic, H pylori-negative ulcers experience a significantly higher rate of recurrent bleeding and mortality compared to those with H pylori-positive ulcers.
- The findings suggest a critical need for monitoring and management strategies for patients with H pylori-negative idiopathic bleeding ulcers due to their increased risks.
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
Francis Ka Leung Chan Vincent Wai Sun Wong Bing Yee Suen Justin Che Yuen Wu Jessica Yuet Ling Ching Dorothy Kai Lai Chow
Lancet
May 2007
Background: Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a non-steroidal anti-inflammatory drug (NSAID) with a proton-pump inhibitor (PPI). These two treatments have similar effectiveness, but they are insufficient for protection of patients at very high risk for ulcer bleeding. We aimed to test the hypothesis that in patients with previous ulcer bleeding induced by non-selective NSAIDs, combined treatment with the COX 2 inhibitor celecoxib and the PPI esomeprazole would be better than celecoxib alone for prevention of recurrent ulcer bleeding.
View Article and Find Full Text PDF